<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143100</url>
  </required_header>
  <id_info>
    <org_study_id>19-06020314</org_study_id>
    <nct_id>NCT04143100</nct_id>
  </id_info>
  <brief_title>Anxiety and Symptom Burden in Hemodialysis Patients</brief_title>
  <official_title>Anxiety, Symptom Burden, and Dialysis Adherence in In-center Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Rogosin Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Rogosin Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anxiety has been identified as a prevalent and significant co-morbid condition in patients&#xD;
      with End Stage Renal Disease (ESRD) being treated with hemodialysis. In particular, anxious&#xD;
      sensitivity to symptoms commonly experienced by dialysis patients may lead patients to&#xD;
      prematurely terminate their dialysis sessions and may have consequences on their dialysis&#xD;
      adequacy and overall quality of life.&#xD;
&#xD;
      The proposed study will examine the relationships between anxiety, depression, quality of&#xD;
      life, symptom burden and dialysis prescription adherence. The primary regression analyses&#xD;
      will be used to predict the influence of anxiety and depression (independently and together)&#xD;
      on measures of adherence behaviors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Additional analyses will examine the relationship of elevated anxiety and depression scores&#xD;
      on symptom burden, QOL, and other measures of dialysis adherence. Retrospective data of the&#xD;
      preceding three months will be used to calculate measures of dialysis adherence (shortening&#xD;
      and skipping) and clinical parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 30, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Generalized Anxiety Disorder-7 (GAD-7)</measure>
    <time_frame>This is a cross-sectional study, with anxiety scores being correlated with previous 6 months of adherence data</time_frame>
    <description>Anxiety measure - higher scores indicate more anxiety</description>
  </primary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Anxiety</condition>
  <condition>ESRD</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey</intervention_name>
    <description>For our primary analysis (multiple regression) scores on the GAD-7, BAI and PHQ-9 will be used to predict dialysis adherence, as defined as minutes reduced (total dialysis prescribed -total actual time on machine) while controlling for age and gender.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving treatment at The Rogosin Institute (Rogosin) hemodialysis treatment&#xD;
        facilities.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Receiving In-center hemodialysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English speaking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cukor, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rogosin Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rogosin Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

